Navigation Links
Optimer Pharmaceuticals Announces Key Additions to Management Team
Date:1/10/2011

r holds a Ph.D. in philosophy, health administration from Columbia Southern, a Master of Public Administration with a specialization in health care from C.W. Post College, and a B.S. in, medical biology also from C.W. Post College.

Hemal Shah has spent more than 10 years in HEOR at Boehringer Ingelheim Pharmaceuticals, most recently as Executive Director, where she was focused on the hospital market for the launch of Spivira® for a chronic obstructive pulmonary disease.  She held positions of increasing responsibility in HEOR, implementing HEOR tools including medication adherence, healthcare reforms, health related quality of life research, health economic model development, and pharmacoeconomic analyses to support arguments for commercialization. Shah received her Doctor of Pharmacy from Rutgers State University and holds a B.S. from the University of Connecticut.

Dr. Womelsdorf has more than 15 years of experience in business development roles at Cyclacel Pharmaceuticals, Johnson & Johnson (J&J), F. Hoffmann-La Roche, Baxter International and, most recently, with his own consulting firm.  As the Vice President, Business Development at Cyclacel, he was responsible for all aspects of corporate and business development and licensing including the repositioning of key programs. During his tenure at J&J, Dr. Womelsdorf closed multiple transactions, including a deal with MGI Pharma that gave J&J rights outside North America to Dacogen™ (decitabine), a late stage oncology product with utility in Myelodysplastic Syndromes, Acute Myeloid Leukemia and other cancers. He was appointed to the Board of Tibotec Therapeutics, J&J's oncology and virology company, where he helped oversee the transition of the Company to a commercial entity culminating in the successful launch of Prezista™ (darunivir), a novel protease inhibitor for the treatment of HIV. Prior to joining J&J, he worked as a Global Licensing Director f
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Optimer Pharmaceuticals Obtains Additional Fidaxomicin Patent
2. Optimer Pharmaceuticals Receives Orphan Drug Designation for Fidaxomicin for the Treatment of Pediatric Clostridium difficile Infection
3. Optimer Pharmaceuticals Appoints Gregory Papaz to New Position of Senior Vice President of Commercial Operations
4. Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
5. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
6. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
7. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
8. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
9. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
10. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
11. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ... CGM System as a non-invasive, wireless continuous glucose monitoring ... Executive Chairman and Interim CEO of Echo Therapeutics, will ... Equity Conference. Mr. Doman will make ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... & Forecast – Worldwide Analysis ... Pump Market Analysis ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... Delivery Systems -- Focus on End Users ... STUDY OBJECTIVES A drug delivery ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... Presented at American Academy of Dermatology Summer ... NeoStrata today announced,findings from an ongoing 12-week ... applied LCD (coal tar) solution (Psorent(TM)) versus,calcipotriol ... psoriasis.,Specifically, results of an interim analysis reveal ...
... 30 An overwhelming number of,Americans with memory ... their,doctors despite visits within the past six months, ... participants in the Alzheimer,s Foundation of,America (AFA) National ... the results at a poster session at the ...
Cached Medicine Technology:Study Reveals Novel LCD Solution Provides Significant Benefits Versus Calcipotriol In Treatment Of Moderate Psoriasis 2Study Reveals Novel LCD Solution Provides Significant Benefits Versus Calcipotriol In Treatment Of Moderate Psoriasis 3Alzheimer's Foundation of America Survey: Americans With Memory Concerns Fall Short of Talking to Doctors 2Alzheimer's Foundation of America Survey: Americans With Memory Concerns Fall Short of Talking to Doctors 3
(Date:7/9/2014)... active in almost all types of cancer sends the ... help fuel a tumour,s uncontrolled growth, new research suggests. ... identified a molecular trigger responsible for ratcheting up activity ... that makes the building blocks cancer cells need to ... pathway, called SREBP, controls the flow of messages to ...
(Date:7/9/2014)... have found that fecal transplantation is effective and safe ... This is the result of a study led by ... Women,s Gastrointestinal Medicine at The Women,s Medicine Collaborative. The ... advance of print in the American Journal of ... C. diff , has increased to epidemic proportions over ...
(Date:7/9/2014)... July 9, 2014 There has been a ... UT Southwestern Medical Center using MyChart, the online, interactive ... results, communicate with their healthcare providers, schedule appointments, and ... of patients actively using MyChart each year ... year increased more than 10-fold, according to a study ...
(Date:7/9/2014)... Allergy and Infectious Diseases (NIAID), part of the ... clinical trial of CRS3123, an investigational oral antibiotic ... C. difficile ) infection. CRS3123 (previously known as ... difficile growth while sparing normal intestinal bacteria. , ... 30 healthy men and women ages 18 to ...
(Date:7/9/2014)... , , , , ... , , , AUDIO: , ... approximately 30cm from the bullet... , , Click here for ... , , , , , ... , , , , , University of Southampton researchers, with assistance from the Ministry of ...
Breaking Medicine News(10 mins):Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 4Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 5Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 6Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 7
... American Cancer Society,is looking for individuals with or without ... the battle against cancer to serve on peer,review committees ... the,organization,s research and training grants. These "stakeholders" have,often had ... had a,family member with cancer, having been a cancer ...
... will show that dental mercury uses contribute to high ... show, for the first time, that dental mercury air,emissions ... US EPA estimates, WASHINGTON, Nov.12 The U.S. ... Reform,Committee will hold a hearing on Wednesday, Nov. 14, ...
... 12 Leading health care risk,management and insurance ... for the period ended Sept. 30, 2007, including ... first nine months of the year. The ... insurance and integrated risk management products,and services for ...
... assistance services affect quality of,patient care, CHICAGO, ... is failing to provide language assistance services required,by ... with the Office for,Civil Rights of the U.S. ... was filed by the American Federation of State, ...
... French . , The Zaire species of Ebolavirus ... species. It alone is responsible for 88% of human ... 1976. It was moreover the species involved in the ... of Congo (DRC) .In spite of the mass of ...
... Nov. 12 Verus Pharmaceuticals, Inc., a,pediatric-oriented specialty pharmaceutical ... to President & Chief Executive Officer.,Prior to the promotion, ... a result of the promotion, Cam L. Garner now ... to announce this well-deserved promotion," said Cam L.,Garner. "As ...
Cached Medicine News:Health News:American Cancer Society Seeks Volunteers to Help Decide Who Gets Research Grants 2Health News:Environmental Impacts of Dental Mercury Focus of U.S. House Oversight Hearing Wednesday 2Health News:FinCor Holdings Posts Double-Digit Increases in Revenue and Net Income for Third Quarter 2Health News:FinCor Holdings Posts Double-Digit Increases in Revenue and Net Income for Third Quarter 3Health News:Language Assistance Lacking at Resurrection Hospitals 2Health News:Language Assistance Lacking at Resurrection Hospitals 3Health News:New genetic lineage of Ebola virus discovered in great apes 2Health News:New genetic lineage of Ebola virus discovered in great apes 3Health News:Verus Pharmaceuticals Announces Promotion of Robert W. Keith to Chief Executive Officer 2Health News:Verus Pharmaceuticals Announces Promotion of Robert W. Keith to Chief Executive Officer 3
... Cougar is an Anterior Spinal Implant ... elasticity approximating that of cortical bone. The ... structural requirements of anterior column support, while ... load sharing design. Incorporates an anatomic design ...
... anterior column support for single or multilevel ... L5. The system consists of one or ... are stacked to a desired height, accommodating ... Reinforced Polymer material emulates the biomechanical properties ...
... provides anterior column support for single or ... to L5. The system consists of one ... that are stacked to a desired height, ... Fiber Reinforced Polymer material emulates the biomechanical ...
Anterior Interbody fusion with proven clinical performance. Large hole design. Request info fda status for sale....
Medicine Products: